reports
- Gary Brode
- Gary Brode
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates ...
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Reported revenue of $16.1 million in the second quarter, representing growth of 11% over the prior year period of 2023;Appointed Greg Firestone as Chief Commercial Officer on May 20, 2024 to drive our...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted purs...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Lockheed Martin Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 August 2024 in which we reassessed the appropriateness of the ratings in the ...
Lockheed Martin Corp: 1 director
A director at Lockheed Martin Corp sold 3,272 shares at 542.717USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Gary Brode
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Co...
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference at 10:30 am ET on August 14th, 2024. Interested parties can access the live and archived webcast at . About TELA Bio...
- Gary Brode
TELA Bio to Announce Second Quarter 2024 Financial Results
TELA Bio to Announce Second Quarter 2024 Financial Results MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...
- MarketLine Department
Terma AS - Company Profile and SWOT Analysis
Summary Terma AS - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Terma AS (Terma) develops, manufactures, and markets advanced structures for defense, and non-defense applications. The company's offerings comprise advanced structures, mission-critical electronics, software,...
- Jonathan Moreland
PAYC PAYCOM SOFTWARE INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
NAD NUVEEN QUALITY MUNICIPAL INCOM
MDB MONGODB INC. CLASS A
PBYI INNOVATIVE ACQUISITIONS CORP
TELA TELA BIO
BIGZ BLACKROCK INNOVATION AND GROWTH TST
EP EMPIRE PETROLEUM CORP
PEO PETROLEUM & RESOURCES CORPORATION
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
TELA Bio Appoints Jeffrey Blizard to its Board of Directors MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we con...
- Valens Research
Valens Equity Weekly Insights - 2024 05 28
Lockheed Martin (LMT) has a long-term profitability tailwind from its multi-decade long F-35 sales cycle, plus growing demand from the U.S. and allies as the world becomes less safe. Uniform Accounting highlights the company's profitability improvements that the market is missing, indicating equity upside. Lockheed is the largest U.S. defense contractor, and it makes high value military equipment including missiles and aircraft like HIMARS and F-35s. Over the last several years, as contract tai...
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
TELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company’s new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company’s commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.